Recent meetings
No recorded meetings with EU commissioners.
Mission & Goals
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply. The company develops and supplies vital technologies to pathogen-protect blood components for blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
EU Legislative Interests
Substances of Human Origin Chemical restrictions impacting medical devices Medical Device Regulation (Regulation (EU) 2017/745 on medical devices) Critical Medicines Act Medical Countermeasures and Preparedness
Communication Activities
8 Feb 2023 virtual event hosted to examine the challenges caused by the current BTC framework and aimed to outline a vision for what an ambitious and protective updated system would look like. Briefs outlining Cerus' position on Substances of Human Origin and the Critical Medicines Act have been distributed.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
https://www.medtecheurope.org/ https://www.bvmed.de/de/english https://bloodtransfusionassociation.org/
Organisation Members
https://www.medtecheurope.org/ https://www.bvmed.de/de/english https://bloodtransfusionassociation.org/